Gas Empowered Dual‐Cascade Strategy for Augmented Single‐Atom Nanotherapies
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202404001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yong Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Analytical Chemistry for Life Science School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, P. R…. Hauptthemen laut MEDLINE: Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Excellent Research Program of Nanjing University.
Abstract (Originalsprache)
Single‐atom nanotherapies have received numerous attention in malignant oncotherapy. However, the insufficient enzyme substrate and the upregulation of heat shock proteins during therapeutic interventions are seldom concurrently noticed. Herein, a novel gas empowered dual‐cascade synergistic treatment strategy is demonstrated with domino effect, which can sequentially reinforce single‐atom nanozyme (SAzyme)‐based enzymatic therapeutics and mild photothermal therapy (PTT) (< 45 °C). In the proof‐of‐concept study, Fe single atom nanozyme (Fe/SAzyme) loaded with hydrogen sulfide (H 2 S) donor NaHS is developed for HSPs‐silencing mediated mild PTT. The generated H 2 S suppresses the catalase activity to achieve “intracellular H 2 O 2 conservation”, thereby furnishing the enzyme substrate to Fe/SAzyme to produce abundant cytotoxic hydroxyl radicals (·OH) for augmented enzymatic therapeutics. Then, excess ·OH induced mitochondrial dysfunction blocks adenosine triphosphate (ATP) energy supply to realize cellular energy remodeling, which hinders overexpression of HSPs and enhances mild PTT of Fe/SAzyme both in vitro and vivo. Consequently, the gas‐triggered dual‐cascade strategy achieves domino H 2 S/·OH/mitochondrial dysfunction synergistic effect, endowing SAzymes with maximum antitumor efficacy via enzymatic therapeutics combined with mild PTT. This dual‐cascaded gas/enzymatic/mild PTT synergistic oncotherapy not only exhibits a new pathway for gas‐facilitated mild PTT, but also offers a valuable paradigm for the application of “1 + 1 + 1 > 3” multimodal synergistic tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Analytical Chemistry for Life Science School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, P. R. China.
- College of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou, 450001, P. R. China.
ORCID-Profile: Jing-Juan Xu
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Excellent Research Program of Nanjing University
- State Key Laboratory of Analytical Chemistry for Life Science
- Fundamental Research Funds for the Central Universities
- National Key Research and Development Program of China
Zitieren
APA
Liu, Y., Li, X. Q., Yu, Q., Kang, B., Zhao, X., & Xu, J. J. (2025). Gas Empowered Dual‐Cascade Strategy for Augmented Single‐Atom Nanotherapies. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202404001
Vancouver
Liu Y, Li XQ, Yu Q, Kang B, Zhao X, Xu JJ. Gas Empowered Dual‐Cascade Strategy for Augmented Single‐Atom Nanotherapies. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202404001
BibTeX
@article{Liu2025,
author = {Liu, Yong and Li, Xiao-Qiong and Yu, Qiao and Kang, Bin and Zhao, Xueli and Xu, Jing-Juan},
title = {Gas Empowered Dual‐Cascade Strategy for Augmented Single‐Atom Nanotherapies},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202404001}
}
EUVIMED